MCID: BRN015
MIFTS: 45

Bronchiolo-Alveolar Adenocarcinoma

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchiolo-Alveolar Adenocarcinoma

MalaCards integrated aliases for Bronchiolo-Alveolar Adenocarcinoma:

Name: Bronchiolo-Alveolar Adenocarcinoma 12 15
Minimally Invasive Lung Adenocarcinoma 12
Adenocarcinoma, Bronchiolo-Alveolar 44
Bronchioloalveolar Adenocarcinoma 73
Bronchioalveolar Lung Carcinoma 12
Bronchioloalveolar Carcinoma 12
Carcinoma Bronchioloalveolar 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4926
MeSH 44 D002282
NCIt 50 C2923
UMLS 73 C0007120

Summaries for Bronchiolo-Alveolar Adenocarcinoma

Disease Ontology : 12 A lung adenocarcinoma characterized by a predominantly lepidic pattern and 5 mm or less invasion in greatest dimension.

MalaCards based summary : Bronchiolo-Alveolar Adenocarcinoma, also known as minimally invasive lung adenocarcinoma, is related to mucinous bronchioloalveolar adenocarcinoma and in situ pulmonary adenocarcinoma, and has symptoms including coughing, dyspnea and fever. An important gene associated with Bronchiolo-Alveolar Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Gastric cancer and MAPK Signaling: Mitogen Stimulation Pathway. The drugs Gemcitabine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and testes, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Related Diseases for Bronchiolo-Alveolar Adenocarcinoma

Diseases related to Bronchiolo-Alveolar Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 119)
# Related Disease Score Top Affiliating Genes
1 mucinous bronchioloalveolar adenocarcinoma 31.8 CDX2 KRT7 NKX2-1
2 in situ pulmonary adenocarcinoma 31.6 EGFR HYAL2
3 mixed mucinous and nonmucinous bronchioloalveolar adenocarcinoma 11.3
4 nonmucinous bronchioloalveolar adenocarcinoma 11.3
5 adenocarcinoma 10.5
6 solid adenocarcinoma with mucin production 10.4 KRT7 NKX2-1
7 ovarian germ cell teratoma 10.4 KRT7 NKX2-1
8 lung acinar adenocarcinoma 10.4 KRT7 NKX2-1
9 small cell carcinoma of the bladder 10.4 KRT7 NKX2-1
10 ovarian germ cell cancer 10.4 KRT7 NKX2-1
11 papillary adenoma 10.4 KRT7 NKX2-1
12 papillary serous adenocarcinoma 10.4 KRT7 NKX2-1
13 intestinal perforation 10.4 KRT7 NKX2-1
14 benign breast adenomyoepithelioma 10.4 EGFR KRT7
15 pulmonary sclerosing hemangioma 10.4 KRT7 NKX2-1
16 oncocytic breast carcinoma 10.3 EGFR KRT7
17 atypical choroid plexus papilloma 10.3 KRT7 NKX2-1
18 sclerosing hemangioma 10.3 KRT7 NKX2-1
19 hepatoid adenocarcinoma 10.3 CDX2 EGFR
20 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
21 ovarian cystic teratoma 10.3 KRT7 NKX2-1
22 vaginal benign neoplasm 10.3 CDX2 KRT7
23 appendix adenocarcinoma 10.3 CDX2 KRT7
24 vaginal adenoma 10.3 CDX2 KRT7
25 vaginal tubulovillous adenoma 10.3 CDX2 KRT7
26 mucinous adenofibroma 10.3 CDX2 KRT7
27 anus adenocarcinoma 10.3 CDX2 KRT7
28 glandular cystitis 10.3 CDX2 KRT7
29 benign mesothelioma 10.3 KRT7 NKX2-1
30 epithelial predominant wilms' tumor 10.3 CDX2 KRT7
31 ovarian mucinous adenocarcinoma 10.2 CDX2 KRT7
32 thymus adenocarcinoma 10.2 CDX2 KRT7
33 gastric diffuse adenocarcinoma 10.2 CDX2 KRT7
34 basaloid squamous cell carcinoma 10.2 EGFR KRT7
35 bladder adenocarcinoma 10.2 CDX2 KRT7
36 jejunal adenocarcinoma 10.2 CDX2 KRT7
37 chronic cystitis 10.2 CDX2 KRT7
38 vulva adenocarcinoma 10.2 CDX2 KRT7
39 mucinous ovarian cystadenoma 10.2 CDX2 KRT7
40 mammary paget's disease 10.2 EGFR KRT7
41 papillary adenocarcinoma 10.2 KRT7 NKX2-1
42 rectum adenocarcinoma 10.2 CDX2 KRT7
43 ampulla of vater adenocarcinoma 10.2 CDX2 KRT7
44 tubular adenocarcinoma 10.2 CDX2 EGFR
45 endocervical adenocarcinoma 10.2 CDX2 KRT7
46 vulva cancer 10.2 EGFR KRT7
47 ovarian mucinous neoplasm 10.2 CDX2 KRT7
48 gastric tubular adenocarcinoma 10.1 CDX2 KRT7
49 signet ring cell adenocarcinoma 10.1 CDX2 KRT7
50 cystitis cystica 10.1 CDX2 KRT7

Graphical network of the top 20 diseases related to Bronchiolo-Alveolar Adenocarcinoma:



Diseases related to Bronchiolo-Alveolar Adenocarcinoma

Symptoms & Phenotypes for Bronchiolo-Alveolar Adenocarcinoma

UMLS symptoms related to Bronchiolo-Alveolar Adenocarcinoma:


coughing, dyspnea, fever, hemoptysis

GenomeRNAi Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 EGFR HYAL2 KRAS KRT7

MGI Mouse Phenotypes related to Bronchiolo-Alveolar Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.8 NKX2-1 CDX2 EGFR HYAL2 KRAS KRT7
2 digestive/alimentary MP:0005381 9.67 NKX2-1 CDX2 EGFR KRAS
3 neoplasm MP:0002006 9.56 NKX2-1 CDX2 EGFR KRAS
4 no phenotypic analysis MP:0003012 9.46 NKX2-1 EGFR HYAL2 KRAS
5 renal/urinary system MP:0005367 9.26 EGFR HYAL2 KRAS KRT7
6 skeleton MP:0005390 9.02 CDX2 EGFR HYAL2 KRAS NKX2-1

Drugs & Therapeutics for Bronchiolo-Alveolar Adenocarcinoma

Drugs for Bronchiolo-Alveolar Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1 41575-94-4 10339178 498142 38904
4
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1 33069-62-4 36314
5
Gefitinib Approved, Investigational Phase 3,Phase 2,Phase 1 184475-35-2 123631
6
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
7
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
9
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
10
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 446556 60843
11
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 216974-75-3
12
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
13
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
14
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
15
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
16 Albumin-Bound Paclitaxel Phase 2, Phase 3,Phase 3,Phase 1
17 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
18 Anti-Infective Agents Phase 3,Phase 2,Phase 1
19 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
20 Antimetabolites Phase 3,Phase 2,Phase 1
21 Antiviral Agents Phase 3,Phase 2,Phase 1
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 2, Phase 3,Phase 3,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 2, Phase 3,Phase 3,Phase 1
25 Epoetin alfa Phase 3 113427-24-0
26 Folic Acid Antagonists Phase 3,Phase 2,Phase 1
27 Mitogens Phase 3,Phase 2
28 Hematinics Phase 3,Phase 2
29 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
30 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
31 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 3,Phase 1
32 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 3,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
34 Vitamin B Complex Phase 3,Phase 2,Phase 1
35 Antibodies Phase 2, Phase 3,Phase 1
36 Immunoglobulins Phase 2, Phase 3,Phase 1
37 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
38 Etoposide phosphate Phase 3,Phase 2,Phase 1
39 Folate Nutraceutical Phase 3,Phase 2,Phase 1
40 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
41
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
42
Vinblastine Approved Phase 2,Phase 1 865-21-4 13342 241903
43
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
44
Mesna Approved, Investigational Phase 2 3375-50-6 598
45
Topotecan Approved, Investigational Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
48
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
49
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
2 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
3 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
4 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
5 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
6 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
7 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
8 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
9 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
10 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
11 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3 cisplatin;docetaxel
12 Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy Terminated NCT01208064 Phase 2, Phase 3 pazopanib hydrochloride
13 Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer Terminated NCT00863512 Phase 3 cisplatin;docetaxel;gemcitabine hydrochloride;pemetrexed disodium;vinorelbine tartrate
14 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer Terminated NCT00004859 Phase 3 carboplatin;paclitaxel;thalidomide
15 Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Withdrawn NCT00054392 Phase 3 carboplatin;gemcitabine hydrochloride;paclitaxel
16 Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer Unknown status NCT00616499 Phase 2 gefitinib
17 Paclitaxel, Carboplatin, and Gefitinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT01024712 Phase 2 carboplatin;gefitinib;paclitaxel
18 Gemcitabine and Cisplatin Before or After Surgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer Unknown status NCT00398385 Phase 2 cisplatin;gemcitabine hydrochloride
19 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma Completed NCT00430261 Phase 2 sunitinib
20 Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00029003 Phase 2 gefitinib
21 Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer Completed NCT00118144 Phase 2 bortezomib
22 Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer Completed NCT00103207 Phase 2
23 Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma Completed NCT00384826 Phase 2 erlotinib;paclitaxel + carboplatine
24 Paclitaxel in Treating Patients With Lung Cancer Completed NCT00002972 Phase 2 paclitaxel
25 S9714: Paclitaxel in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00002969 Phase 2 paclitaxel
26 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00416650 Phase 2 erlotinib hydrochloride
27 MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy Completed NCT01294306 Phase 2 Akt Inhibitor MK2206;Erlotinib Hydrochloride
28 Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions Completed NCT03097627 Phase 1, Phase 2 ICG Intervention
29 Bevacizumab, Pemetrexed Disodium, and Cisplatin or Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). Completed NCT01116219 Phase 2 bevacizumab, pemetrexed, cisplatin
30 Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00411047 Phase 2 gefitinib
31 Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer Completed NCT00103116 Phase 2
32 Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer Completed NCT00003666 Phase 2 6-hydroxymethylacylfulvene
33 Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function Completed NCT00002624 Phase 2
34 Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT01557959 Phase 2 cisplatin;erlotinib hydrochloride;docetaxel
35 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00368992 Phase 2 paclitaxel
36 Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00040794 Phase 2 paclitaxel;carboplatin;gefitinib
37 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers Completed NCT01344824 Phase 2 carboplatin;erlotinib hydrochloride;pemetrexed disodium
38 Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00553462 Phase 2 carboplatin;erlotinib hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation
39 Imatinib Mesylate and Bevacizumab After First-Line Chemotherapy and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Completed NCT00425646 Phase 2 imatinib mesylate
40 Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed NCT00970684 Phase 2 docetaxel;gemcitabine hydrochloride
41 Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00309998 Phase 2 vinorelbine tartrate
42 Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy Completed NCT00365547 Phase 2 topotecan hydrochloride
43 Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC Completed NCT00354549 Phase 2 bevacizumab + erlotinib hydrochloride;gemcitabine hydrochloride + cisplatin or carboplatin
44 Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed NCT00117962 Phase 2 carboplatin;pemetrexed disodium
45 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer Completed NCT00087438 Phase 2
46 Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00081302 Phase 2 carboplatin;paclitaxel
47 Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed NCT00033553 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
48 Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Completed NCT00010218 Phase 2 karenitecin
49 Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT00278460 Phase 2 docetaxel;gemcitabine hydrochloride
50 Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Completed NCT01302808 Phase 1, Phase 2 erlotinib hydrochloride;romidepsin

Search NIH Clinical Center for Bronchiolo-Alveolar Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, bronchiolo-alveolar

Genetic Tests for Bronchiolo-Alveolar Adenocarcinoma

Anatomical Context for Bronchiolo-Alveolar Adenocarcinoma

MalaCards organs/tissues related to Bronchiolo-Alveolar Adenocarcinoma:

41
Lung, Brain, Testes, Heart

Publications for Bronchiolo-Alveolar Adenocarcinoma

Articles related to Bronchiolo-Alveolar Adenocarcinoma:

# Title Authors Year
1
Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes. ( 11259097 )
2001
2
Primary bronchiolo-alveolar adenocarcinoma in a dromedary camel (Camelus dromedarius). ( 9549871 )
1998
3
Primary bronchiolo-alveolar adenocarcinoma in a bull. ( 8677609 )
1996
4
Bronchiolo-alveolar adenocarcinoma in a horse. ( 2562160 )
1989
5
Bronchiolo-alveolar adenocarcinoma with multiple cysts. ( 6287799 )
1982

Variations for Bronchiolo-Alveolar Adenocarcinoma

Cosmic variations for Bronchiolo-Alveolar Adenocarcinoma:

9
(show top 50) (show all 13386)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926570 ZRSR2 lung,NS,carcinoma,adenocarcinoma c.937+1G>T p.? 23:15820317-15820317 12
2 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 3:50345197-50345197 12
3 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 3:50342996-50342996 12
4 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 13:19993167-19993167 12
5 COSM6145051 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.562G>T p.A188S 16:72959584-72959584 12
6 COSM6978013 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1855C>G p.H619D 16:72958291-72958291 12
7 COSM6975161 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5985C>G p.I1995M 16:72796697-72796697 12
8 COSM6932802 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2842G>T p.A948S 16:72950843-72950843 12
9 COSM6954614 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6293C>T p.S2098L 16:72796389-72796389 12
10 COSM6967535 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3070G>T p.A1024S 16:72950615-72950615 12
11 COSM6933870 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3763C>T p.P1255S 16:72811678-72811678 12
12 COSM6926444 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10766C>G p.S3589C 16:72787510-72787510 12
13 COSM6933260 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.256G>T p.A86S 16:72959890-72959890 12
14 COSM6950021 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2135G>T p.R712L 16:72958011-72958011 12
15 COSM6965155 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.331G>A p.E111K 16:72959815-72959815 12
16 COSM6972801 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2680G>T p.D894Y 16:72957466-72957466 12
17 COSM6982281 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2701G>A p.A901T 16:72957445-72957445 12
18 COSM6937412 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1775A>C p.D592A 16:72958371-72958371 12
19 COSM6969901 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10802C>T p.S3601L 16:72787474-72787474 12
20 COSM6964729 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5670G>C p.Q1890H 16:72797012-72797012 12
21 COSM6931279 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1530G>T p.E510D 16:72958616-72958616 12
22 COSM6935718 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10628C>A p.A3543D 16:72787648-72787648 12
23 COSM6929247 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8677G>C p.G2893R 16:72794005-72794005 12
24 COSM6945078 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2755G>T p.G919C 16:72950930-72950930 12
25 COSM6935881 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1352G>T p.C451F 16:72958794-72958794 12
26 COSM6940635 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.6289T>G p.F2097V 16:72796393-72796393 12
27 COSM6969446 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.628G>T p.G210C 16:72959518-72959518 12
28 COSM6968693 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2767G>T p.V923L 16:72950918-72950918 12
29 COSM6926443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10885C>G p.P3629A 16:72787391-72787391 12
30 COSM6962405 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10961C>T p.S3654L 16:72787315-72787315 12
31 COSM6970007 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3340C>G p.R1114G 16:72889839-72889839 12
32 COSM6977567 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4834G>C p.E1612Q 16:72797848-72797848 12
33 COSM5796563 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.445C>T p.Q149* 16:72959701-72959701 12
34 COSM6966467 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.5788T>C p.S1930P 16:72796894-72796894 12
35 COSM6970295 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1910G>A p.G637E 16:72958236-72958236 12
36 COSM6968715 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.8982C>G p.F2994L 16:72793700-72793700 12
37 COSM6982440 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1582C>T p.Q528* 16:72958564-72958564 12
38 COSM6983995 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7133C>G p.T2378S 16:72795549-72795549 12
39 COSM6962938 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.4181C>A p.S1394* 16:72798501-72798501 12
40 COSM6937443 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.7769C>G p.S2590C 16:72794913-72794913 12
41 COSM6953061 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.10994A>T p.D3665V 16:72787282-72787282 12
42 COSM6953714 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.3431G>T p.C1144F 16:72889748-72889748 12
43 COSM6969956 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.527G>T p.G176V 16:72959619-72959619 12
44 COSM4062722 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2486T>C p.M829T 16:72957660-72957660 12
45 COSM6939807 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.1408G>T p.E470* 16:72958738-72958738 12
46 COSM6956103 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.2437A>T p.T813S 16:72957709-72957709 12
47 COSM6826441 ZFHX3 lung,NS,carcinoma,adenocarcinoma c.941G>A p.R314Q 16:72959205-72959205 12
48 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 2:97737758-97737758 12
49 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 17:1364977-1364977 12
50 COSM49006 YES1 lung,NS,carcinoma,adenocarcinoma c.371+1G>T p.? 18:751704-751704 12

Expression for Bronchiolo-Alveolar Adenocarcinoma

Search GEO for disease gene expression data for Bronchiolo-Alveolar Adenocarcinoma.

Pathways for Bronchiolo-Alveolar Adenocarcinoma

GO Terms for Bronchiolo-Alveolar Adenocarcinoma

Cellular components related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 8.96 EGFR HYAL2
2 membrane raft GO:0045121 8.8 EGFR HYAL2 KRAS

Biological processes related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 9.4 EGFR HYAL2
2 positive regulation of MAP kinase activity GO:0043406 9.37 EGFR KRAS
3 epidermal growth factor receptor signaling pathway GO:0007173 9.32 EGFR KRAS
4 pattern specification process GO:0007389 9.26 CDX2 NKX2-1
5 ERBB2 signaling pathway GO:0038128 9.16 EGFR KRAS
6 epithelial tube branching involved in lung morphogenesis GO:0060441 8.96 KRAS NKX2-1
7 cerebral cortex cell migration GO:0021795 8.62 EGFR NKX2-1

Molecular functions related to Bronchiolo-Alveolar Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 8.96 EGFR HYAL2
2 enzyme binding GO:0019899 8.8 EGFR HYAL2 NKX2-1

Sources for Bronchiolo-Alveolar Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....